TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 173 filers reported holding TRAVERE THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 1.37 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,688,990 | +93.4% | 188,925 | +232.3% | 0.06% | +97.0% |
| Q2 2023 | $873,339 | +229.6% | 56,858 | +428.6% | 0.03% | +230.0% |
| Q3 2022 | $265,000 | -82.0% | 10,757 | -82.3% | 0.01% | -84.4% |
| Q2 2022 | $1,471,000 | +40.6% | 60,700 | +49.5% | 0.06% | +42.2% |
| Q1 2022 | $1,046,000 | +230.0% | 40,600 | +296.9% | 0.04% | +125.0% |
| Q4 2021 | $317,000 | +64.2% | 10,228 | -22.5% | 0.02% | +5.3% |
| Q2 2021 | $193,000 | – | 13,200 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 895,821 | $8,008,640 | 3.99% |
| Deep Track Capital, LP | 7,370,000 | $65,887,800 | 2.54% |
| VR Adviser, LLC | 2,623,677 | $23,455,672 | 2.47% |
| Sio Capital Management, LLC | 884,770 | $7,909,844 | 2.45% |
| Kynam Capital Management, LP | 957,502 | $8,560,068 | 1.40% |
| MPM BioImpact LLC | 552,846 | $4,942,443 | 1.32% |
| ARMISTICE CAPITAL, LLC | 7,500,000 | $67,050,000 | 1.03% |
| Parkman Healthcare Partners LLC | 577,494 | $5,162,796 | 0.95% |
| Tri Locum Partners LP | 251,702 | $2,250,216 | 0.72% |
| Cheyne Capital Management (UK) LLP | 26,200 | $234,228 | 0.68% |